Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Russinko

Urology Lancaster, PA Medical Doctor

NPI 1720041981 CMS profile 259976

2106 Harrisburg Pike, Suite 200, Lancaster, PA 17601

Open in the dashboard

General payments

$4,042

202 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

3 holdings reported · through program year 2025

Through program year 2025, Paul Russinko of Lancaster, PA is reported in the CMS Open Payments database as having received $4,042 across 202 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,121 44
2024 General $509 27
2023 General $898 46
2022 General $671 37
2021 General $409 27
2020 General $274 10
2019 General $160 11
2021 Ownership $0 1
2020 Ownership $0 1
2019 Ownership $0 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Russinko
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Paul Russinko were reported at $1,121. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Paul Russinko Urology median Middle half National median
2019 $160 $480 $147–$1,201 $163
2020 $274 $246 $87–$645 $114
2021 $409 $358 $111–$1,000 $132
2022 $671 $476 $143–$1,263 $149
2023 $898 $560 $168–$1,461 $160
2024 $509 $563 $170–$1,464 $164
2025 $1,121 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $588 43 payments
  2. Astellas Pharma US Inc $416 24 payments
  3. Janssen Biotech, Inc. $329 20 payments
  4. Urogen Pharma, Inc. $267 14 payments
  5. Dendreon Pharmaceuticals LLC $236 8 payments
  6. Merck Sharp & Dohme Corporation $235 13 payments
  7. Immunitybio, Inc. $217 5 payments
  8. Sumitomo Pharma America, Inc. $167 9 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $148 8 payments
  10. Novo Nordisk Inc $122 1 payment
  11. Other $1,317 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,977 201 payments
  2. Education $65 1 payment
Products named General payments · program years 2019–2025
  1. XTANDI $849 60 payments
  2. ORGOVYX $540 39 payments
  3. ERLEADA $329 20 payments
  4. TALZENNA $249 16 payments
  5. JELMYTO $245 13 payments
  6. PROVENGE $236 8 payments
  7. KEYTRUDA $205 11 payments
  8. ANKTIVA $201 4 payments
  9. LYNPARZA $189 10 payments
  10. Xofigo $148 8 payments
  11. Other $2,542 120 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,985

Median for Urology: 1,053

Drug cost

$255,673

Median for Urology: $101,464

Branded share of claims

35.6%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 153 $139,403
Orgovyx Relugolix Brand 17 $43,799
Gemtesa Vibegron Brand 40 $34,385
Alfuzosin Hcl Er Alfuzosin Hcl Brand 351 $8,302
Dutasteride Generic 126 $5,918
Finasteride Generic 422 $5,189
Tamsulosin Hcl Generic 348 $4,976
Fesoterodine Fumarate Er Fesoterodine Fumarate Brand 11 $2,877
Darifenacin Er Darifenacin Hydrobromide Brand 11 $2,264
Potassium Citrate Er Potassium Citrate Brand 24 $2,176

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 110 billing codes

Paid by Medicare

$582,667

Of which drugs: $226,109

Medicare patients

2,084

Average age 76

Services billed

30,834

498 women, 1,586 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Cancer 34%
Ischemic heart disease 32%
Chronic kidney disease 32%
Diabetes 31%
Atrial fibrillation 22%
Depression 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide injectable, camcevi, 1 mg J1952 Office 73 3,318 $142,883
Injection, denosumab, 1 mg J0897 Office 39 2,670 $55,497
Bcg live intravesical instillation, 1 mg J9030 Office 11 2,360 $5,269
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 77 9,200 $868

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JELMYTO
  • UROGEN PHARMA, INC. $99
$99 — —
ORGOVYX
  • PFIZER INC. $27
  • Sumitomo Pharma America, Inc. $17
$44 17 —
BOTOX
  • AbbVie, Inc. $43
$43 — —
XTANDI
  • PFIZER INC. $27
$27 — —
TALZENNA
  • PFIZER INC. $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

202 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record